KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) EBITDA: 2014-2024

Historic EBITDA for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Dec 2024 value amounting to $5.8 million.

  • Aurinia Pharmaceuticals' EBITDA rose 113.89% to $31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.5 million, marking a year-over-year increase of 452.31%. This contributed to the annual value of $5.8 million for FY2024, which is 107.51% up from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported EBITDA of $5.8 million as of FY2024, which was up 107.51% from -$77.7 million recorded in FY2023.
  • Aurinia Pharmaceuticals' 5-year EBITDA high stood at $5.8 million for FY2024, and its period low was -$181.0 million during FY2021.
  • Its 3-year average for EBITDA is -$60.1 million, with a median of -$77.7 million in 2023.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' EBITDA slumped by 76.29% in 2021, and later skyrocketed by 107.51% in 2024.
  • Over the past 5 years, Aurinia Pharmaceuticals' EBITDA (Yearly) stood at -$102.7 million in 2020, then crashed by 76.29% to -$181.0 million in 2021, then skyrocketed by 40.12% to -$108.4 million in 2022, then increased by 28.32% to -$77.7 million in 2023, then surged by 107.51% to $5.8 million in 2024.